Kanjinti (trastuzumab-anns)

**Product type:** Human Prescription Drug

**Active ingredient:** TRASTUZUMAB

**Strength:** 150 mg/7.15mL

**Dosage form:** Injection, Powder, Lyophilized, For Solution

**Route:** Intravenous

**Labeler:** Amgen, Inc

**Marketing category:** BLA (BLA761073)

**Pharmacologic class:** HER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC]